ERBB2 and breast cancer: In women with treatments, HER2+ (adjusted HR 2.18; 95% CI 1.46 to 3.28; P = 0.0001) and TNBC (1.5; 95% CI 1.11 to 2.04; P = 0.0091) subtypes were significantly associated with the decreased survival by multivariable analysis adjusting for age, tumor size and grade, number of positive nodes, stage and breast cancer subtypes (Table 3).